Merchavia

Juventas Therapeutics Inc

Juventas Therapeutics is a private, clinical stage biotechnology company developing novel non-viral gene therapies that activate natural processes to repair the body. Our product candidate, JVS-100, is a non-viral gene therapy that expresses stromal cell-derived factor-1, or SDF-1, a naturally occurring signaling protein that has been shown to recruit the body’s own stem cells and promote tissue repair in a broad range of disease states. Juventas’ therapeutic approach is based on research originating at the Cleveland Clinic. Juventas did not meet the end point criteria in its Phase 2b study in patients with advanced peripheral artery disease.

Juventas currently seeking to license out 2 remain indications which are in pre-clinical stage, muscle repair and dermal scaring.